FOSTER CITY – The U.S. President’s Emergency Plan for AIDS Relief (PEPFAR) and The Global Fund to Fight AIDS, Tuberculosis and Malaria have committed additional investment to expand the global availability of Gilead Sciences’ Lenacapavir.
The strategic funding aims to scale the distribution of the long-acting HIV prevention medication, targeting populations in high-burden regions where traditional daily oral regimens face adherence challenges. The initiative will be implemented through country HIV programs that are already aligned with the World Health Organization’s consolidated guidelines on HIV prevention, testing, treatment and care, allowing Lenacapavir to be evaluated and deployed alongside existing oral PrEP options.
This investment shifts the economic model of HIV prevention toward long-acting therapeutics, reducing the logistical burden on healthcare infrastructure in low- and middle-income countries while securing a wider market footprint for Gilead’s capsid inhibitor technology. It also signals to national health ministries and procurement agencies that long-acting products are moving from pilot projects into the core architecture of donor-financed HIV prevention.
Strategic Shift in Prevention Therapeutics
Lenacapavir represents a departure from standard Pre-Exposure Prophylaxis (PrEP) by utilizing a capsid inhibitor mechanism. Unlike daily pills, this medication is administered via injection on an extended dosing schedule, which alters the delivery requirements and patient monitoring cycles for health providers and may lessen the dependence on daily patient adherence.
The move by PEPFAR and The Global Fund focuses on the following operational goals:
- Expanding procurement capabilities for Lenacapavir in targeted global markets, particularly in countries with generalized epidemics and high incidence among key populations.
- Integrating long-acting injectables into existing public health delivery systems, including community clinics and differentiated service delivery models.
- Increasing access for high-risk populations to reduce new HIV infection rates, while generating early implementation data that can inform future country guidelines and global recommendations.
“The investment by PEPFAR and The Global Fund is a critical step toward ensuring that this innovative prevention option reaches the people who need it most,”
Gilead stated regarding the collaboration, framing the agreement as both a public‑health intervention and a proof point for long-acting HIV prevention at scale.
Corporate Market Positioning
Gilead Sciences maintains a dominant position in the global antiviral market, with its HIV portfolio serving as a primary revenue driver. The integration of Lenacapavir into large-scale international funding streams allows the company to leverage public-sector financing to establish the drug’s utility in diverse regulatory and epidemiological environments, from sub-Saharan Africa to parts of Asia and Latin America.
The involvement of PEPFAR provides a structured procurement pipeline under U.S. foreign assistance authorities such as the U.S. Leadership Against HIV/AIDS, Tuberculosis, and Malaria Act, which mitigates the financial risk associated with entering markets with limited private insurance coverage or low per-capita healthcare spending. That framework also ties product uptake to country operational plans and performance indicators, creating clearer accountability for both Gilead and recipient governments.
The Global Fund’s participation further stabilizes the supply chain by providing the necessary capital to manage the cold-chain logistics and clinical training required for injectable administrations. By embedding Lenacapavir within multi‑year grant cycles, the institution can support demand forecasting, pooled procurement and price negotiations that influence how quickly the product becomes affordable at scale.
Regulatory and Infrastructure Integration
The scale-up of Lenacapavir requires alignment with national regulatory authorities and with global guidance for HIV prevention. The additional investment will support the technical transition from oral-based PrEP to injectable frameworks, including updates to national treatment guidelines, pharmacovigilance systems and monitoring tools used to track coverage and outcomes.
Corporate governance for this rollout involves coordinated efforts between Gilead and its licensing partners to ensure that manufacturing capacity meets the increased demand generated by these international funding commitments, while also addressing potential intellectual property and pricing questions in lower-income markets.
The deployment of these funds is tied to specific milestones in drug accessibility and the establishment of delivery protocols in partner nations, such as the number of sites offering injectable PrEP and the integration of Lenacapavir into routine counseling and testing services.
The program remains subject to the funding cycles of the participating international health organizations and the regulatory approval timelines for specific regional markets. Any delays in national authorization, pricing negotiations or donor replenishments could affect the pace at which Lenacapavir moves from donor-financed pilots to a sustained component of countries’ HIV prevention strategies.
